Mattis Ranthe - ExpreS2ion Biotech Chief Officer

All Insiders . Sweden . 
Stock . ExpreS2ion Biotech Holding . Stakeholders . Insider . Mattis Ranthe
EXPRS2 Stock  SEK 4.66  -0.32  -6.43%   

Insider

Mattis Ranthe is Chief Officer of ExpreS2ion Biotech Holding
Phone45 22 22 10 19
Webhttps://www.expres2ionbio.com

ExpreS2ion Biotech Management Efficiency

The company has return on total asset (ROA) of -55.13 % which means that on every $100 spent on assets, it lost $55.13. This is very low relative to industry peers. Similarly, it shows a return on equity (ROE) of -97.35 %, which implies that shareholder value decreased during the period.
ExpreS2ion Biotech Holding has accumulated SEK3.48 M in total debt with debt to equity ratio (D/E) of 10.4, indicating ExpreS2ion Biotech may have difficulties to generate enough cash to satisfy its financial obligations. ExpreS2ion Biotech has a current ratio of 2.57, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ExpreS2ion Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, ExpreS2ion Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ExpreS2ion Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt can serve as one financing mechanism for ExpreS2ion to fund growth, though the effectiveness depends on borrowing costs and execution. When we think about ExpreS2ion Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Sara ThuressonGuard Therapeutics Internationa
N/A
Magnus MrtenssonOrtivus AB ser
N/A
Ronny RenfurmGuard Therapeutics Internationa
N/A
Pr LaurellAcouSort AB
62
Mats JonassonFluicell AB
67
Jonas HannestadFluicell AB
42
AnnKristin MydeGuard Therapeutics Internationa
N/A
Michael ReuschGuard Therapeutics Internationa
63
Philip SwanOrtivus AB ser
57
Jonas BerghOrtivus AB ser
52
Thomas PasoldOrtivus AB ser
63
Magnus GramGuard Therapeutics Internationa
43
Torbjorn LarssonGuard Therapeutics Internationa
N/A
Victoire ViannayFluicell AB
48
Markus MDOncozenge AB
71
Mark Gray2cureX AB
53
Mark BeveridgeOncozenge AB
45
Reidar GardebackOrtivus AB ser
60
Elisabeth AugustssonGuard Therapeutics Internationa
54
Ole VD2cureX AB
70
Fredrik LehmannGuard Therapeutics Internationa
43
ExpreS2ion Biotech Holding AB , through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark. ExpreS2ion Biotech operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 15 people. ExpreS2ion Biotech Holding (EXPRS2) is listed on Stockholm Exchange in Sweden.

Management Performance

Return On Equity-0.97
Return On Asset-0.55

ExpreS2ion Biotech Leadership Team

Elected by the shareholders, the ExpreS2ion Biotech's board of directors comprises two types of representatives: ExpreS2ion Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ExpreS2ion. The board's role is to monitor ExpreS2ion Biotech's management team and ensure that shareholders' interests are well served. ExpreS2ion Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ExpreS2ion Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Alexander, Chief Officer
Lars Petersen, Medical Oncology
Mette Thorn, VP Devel
Bent MSc, Chief Officer
Mattis Ranthe, Chief Officer
Max Sogaard, Dev Research

ExpreS2ion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ExpreS2ion Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.97
Return On Asset-0.55
Operating Margin-20.75 %
Current Valuation361.15 M
Shares Outstanding37.15 M
Shares Owned By Institutions1.75 %
Price To Book3.42 X
Price To Sales55.94 X
Revenue12.23 M
Gross Profit1.07 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization surfaces companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

More Resources for ExpreS2ion Stock Analysis

Other Information on Investing in ExpreS2ion Stock

These ratios describe connections between financial data points for ExpreS2ion Biotech. This data is based on the latest available financial reporting cycle.
Macroaxis provides analytical tools and reference data for investors of all levels to evaluate holdings and assess risk across market volatility, economic shifts, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY